Adicet Bio receives FDA clearance for ADI-270 IND in renal cell carcinoma; Phase 1 trial planned for H2 2024

Adicet Bio, Inc.

ADI-270 is the first gamma delta 1 CAR T cell therapy to enter clinical trials for solid tumors.
Phase 1 multicenter, open-label trial in relapsed/refractory clear cell RCC to start in H2 2024; preliminary data expected H1 2025.
ADI-270 is an armored allogeneic off-the-shelf CAR T targeting CD70+ cancers designed for high specificity and tumor infiltration.
Trial will evaluate safety, tolerability, pharmacokinetics, overall response rate, duration of response, and disease control rate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.